PRS40 THE IMPACT OF THE FDA'S RISK EVALUATION AND MITIGATION STRATEGIES (REMS) INITIATIVE ON PRESCRIPTION PATTERN FOR DRUGS APPROVED UNDER THE REMS PROGRAM AND RELEVANT NON-REMS COMPETITORS
Horowicz-Mehler N 1 , Sepulveda B 1 , White C 1 , Doyle J 2 1 Quintiles, Hawthorne, NY, USA, 2 Quintiles Global Consulting, Hawthorne, NY, USA OBJECTIVES: To assess the impact of REMS approval on prescription pattern for three oral drugs used to treat common chronic conditions. We assessed relative impact on prescription volume for REMS-approved drugs against relevant competitors not requiring REMS. We described these trends over the [2006] [2007] [2008] [2009] period including the 9/27/2007 implementation of the REMS initiative. METHODS: We paired two top prescribed drugs for the treatment of asthma (Advair/Singulair), diabetes (Actos/ Avandia) and insomnia (Ambien/Lunesta). Each pairing included a REMS-approved drug (Advair, Actos and Ambien). We focused on the months leading to and following REMS approvals. For each pairing, volume of total prescriptions (TRx), new prescriptions (NRx) and prescription switches (SRx) were collected using the Verispan's VONA database. Statistical analyses were performed using one-way ANOVA. RESULTS: There were no significant changes (p < 0.05) in the volume of TRx, NRx and SRx for Advair or Actos prior to or following approval. However, Ambien TRx were significantly higher during and after the last quarter of 2008 compared to previous months (p = .008) while SRx were lower (p = 0.04). This increase did not come to the expense of Lunesta whose prescription volume stayed constant over the time period considered. CONCLUSIONS: The fear that additional safety requirements could be detrimental to drug prescriptions was not confirmed in our analyses. In fact, FDA requirement for REMS approval appeared to impact prescription volume favorably for one of the drugs considered. One possible explanation is the potential for increased interactions with providers thus the ability to better position the drug clinically. However, these trends were observed with less than a two-year period postapproval and only for a handful of drugs and conditions. Additionally, the differential impact of various REMS components such as medical guide and communication plan should be further investigated.
PRS41 NATIONAL ANTI-ALLERGIC DRUG UTILIZATION PATTERNS IN ADULTS WITH ALLERGIC RHINITIS: NATIONAL AMBULATORY CARE SURVEY RESULTS.
Goyal RK, Patel HK, Sangani D, Aparasu RR University of Houston, Houston, TX, USA OBJECTIVES: To examine recent anti-allergic drug utilization patterns in adult patients with allergic rhinitis using National Ambulatory Care Survey data. METHODS: Data for this study was obtained from the 2006 and 2007 National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS) public use data files. Visits with a primary diagnosis of allergic rhinitis in adults (age >18 years) were identified. Descriptive weighted statistics was used to examine utilization patterns of various anti-allergic medications. A multivariate survey logistic was conducted to determine demographic and geographic variations associated with anti-allergic medication use in patients with allergic rhinitis. RESULTS: Allergic rhinitis accounted for 18.6 million adult ambulatory care visits in the United States. The majority of the visits were made by females (61.6%), whites (84.8%), and involved specialists (59.9%). Anti-allergic medications were prescribed in 55.1% (95%CI 39.2% −71.0%) of the total diagnosed visits. Antihistamines were the most commonly prescribed anti-allergic medication (37.4%) (95%CI 32.4%-46.5%) followed by intranasal steroids (28.3%) (95%CI 23.2%-31.8%). Topical nasal antihistamines and decongestants (7.8%) (95%CI 2.7%-9.9%), leukotrienes (6.3%) (95%CI 5.2%-6.8%), corticosteroids (3.4%) (95%CI 1.3%-4.3%), and oral decongestants (1.52%) (95%CI 0.4%-2.1%) were the least prescribed antiallergic medications. The multivariate logistic regression revealed that geographic region of the office visits was significantly associated with medication use. Outpatient visits in the Midwest (Odds Ratio (OR) 5.16, 95%CI 1.50-17.67), South (OR 6.3, and West (OR 9.16, ) regions were more likely to be prescribed anti-allergic medications compared to those in the Northeast region. CONCLUSIONS: Anti-allergic medications were prescribed in over half of adult allergic rhinitis visits in the U.S. The findings highlight geographical variations in anti-allergic medication use for allergic rhinitis. Comprehensive research is needed to understand the reasons for geographic variation in the medication use for allergic rhinitis.
PRS42 IMPACT OF THE UK PUBLIC SMOKING BAN ON THE PRESCRIBING OF SMOKING CESSATION THERAPY IN PRIMARY CARE-A THIN DATABASE STUDY
Blak BT, Hards M, Thompson M, Dattani H CSD EPIC, London, UK OBJECTIVES: Over-the-counter nicotine replacement purchases increased immediately after the public smoking ban introduction in Scotland. The study objective was to evaluate the impact of the smoking bans throughout the UK on smoking cessation prescriptions (SCPs) or related general practice contacts (GPCs) in primary care. METHODS: Monthly data on SCPs (nicotine replacement therapy, bupropion, varenicline) and GPCs were obtained from The Health Improvement Network (THIN) database, which holds anonymised longitudinal UK primary care data, 24 months before and after the ban in England (January 7, 2007), Wales (February 4, 2007) , Scotland (March 26, 2006) and Northern Ireland (NI) (April 30, 2007) . The percentage of active patients with ≥1 SCP and the percentage of GPCs which were smoking cessation-related were evaluated. Mann-Whitney tests compared percentages before and after the ban. RESULTS: Within each country SCPs increased slightly after the smoking ban, for example during the total 48 months 431,675 SCPs were prescribed in England, with 48.7% prescribed before the ban and 51.3% after. The median percentage of patients with ≥1 SCP increased slightly after the ban-in England the median was 0.28% before and 0.31% after, with no evidence of a difference (p = 0.18), in Wales 0.36% and 0.49% (p = 0.001) respectively, Scotland 0.36% and 0.37% (p = 0.85), and NI 0.48% and 0.54% (p = 0.09). The median percentage of GPCs decreased slightly-in England it was 1.87% before and 1.57% after, Wales 2.08% and 1.81% respectively, Scotland 2.70% and 1.64%, and NI 2.95% and 2.34%. There was evidence of a difference (p < 0.0001) in each country. CONCLU-SIONS: The ban did not seem to impact smoking cessation activity in primary care greatly. Even though only significant for Wales, the slight increase in patients with SCPs may be owing to the ban. The decrease in smoking-related GPCs could be owing to patients being referred to or seeking support outside of primary care.
PRS43 PRESCRIBING ANTIBIOTICS FOR ACUTE RESPIRATORY TRACT INFECTIONS BY PRIMARY CARE PHYSICIANS IN NEW DELHI, INDIA
Kotwani A 1 , Roy Chaudhury R 2 , Holloway K 3 1 Vallabhbhai Patel Chest Institute, Univ of Delhi, Delhi, India, 2 Indraprastha Apollo Hospitals, New Delhi, India, 3 World Health Organisation, Geneva, Switzerland OBJECTIVES: In the absence of community-based databases on antibiotic use in developing countries recently a methodology was established for surveillance of antibiotic use at New Delhi by conducting 'Exit Interviews' of the patients. This study was conducted to obtain information on current prescribing rates of antibiotics in acute respiratory illnesses (ARI), a condition where misuse of antibiotics is common. METHODS: Antibiotic use data was collected from public and private sector facilities from four municipal wards (residential localities) around a tertiary care hospital where the antibiotic resistance work was being conducted. For public sector, 8 dispensaries (primary health care) and 2 secondary care level facilities were enrolled. For private sector, 20 willing and cooperative general practitioners and specialists practising in the chosen areas were selected. Patients after consultation with prescriber were asked if they had cough/common cold/sore throat (symptoms of ARI). Patients with any of these symptoms were enrolled for exit interview and his/her prescription was monitored. Antibiotic use data was collected per month over one year (December 2007 -November 2008 .The percentage of patients receiving antibiotic and pattern of consumption for various antibiotics was analysed. RESULTS: At public facilities 45.3% (746/1646) and at private facilities 56.7% (259/457) of patients with ARI were prescribed at least one antibiotic. In public sector, macrolides (29.3%), penicillins (26.3%), and cephalosporins (16.2%) and in private sector, cephalosporins (40%), fluoroquinolones (21.7%), and penicillins (19.7%) were mainly prescribed. At public facilities, main members from macrolides were roxithromycin and erythromycin; for penicillins, amoxicillin and amoxicillin+clavulinic acid; for cephalosporins, cefuroxime and cephalexin were used. At private clinics, for cephalosporins, cefuroxime, cefpodoxime proxetil, cefixime, cefixime+clavulinic acid; for fluoroquinolones, levofloxacin and ofloxacin; and for penicillins group amoxicillin+clavulinic acid were prescribed. CONCLUSIONS: Over-prescription and irrational use of antibiotics was seen in ARI. In-depth behaviour study for prescribers and strategies to manage ARI are needed.
PRS44 ANTIBIOTIC PRESCRIBING FOR ACUTE RESPIRATORY TRACT INFECTIONS IN ADULT PRIMARY CARE: IS GOOD INSURANCE BAD FOR ANTIBIOTIC PRESCRIBING?
Zhang J 1 , Tao J 2 1 Virginia Commonwealth University, Richmond , VA, USA, 2 Virginia Commonwealth University, Richmond, VA, USA OBJECTIVES: Substantial overuse of newer broad-spectrum antibiotics has been a grave public health concern as it results in drug resistance and substantial health care costs. Little is known about how health insurance status is related with the prescribing of antibiotics at the adult primary care. We aim to assess the relationship between broad-spectrum antibiotic prescribing and patients' insurance status in treatment of acute respiratory tract infections (ARTI) in adult primary care using a nationally representative sample. METHODS: We analyzed 2006 National Ambulatory Medicare Care Survey, for adult aged 18 years or older cared for ARTI. Those patients with a concomitant diagnosis with other common outpatient infections that might be treated with antibiotics were excluded. Analysis was restricted to those patient visitation cared by physician specialty with general practice, family practice, and internal medicine. Multivariate logit regression analysis was performed to assess the relationship between patient insurance status and the prescribing of broad-spectrum antibiotics controlling for age, gender, race and ethnicity, physician specialty, and comorbidities. RESULTS: Of 851 adults patients care for ARTI, 38% were prescribed one or more broad-spectrum antibiotics. In multivariate regression analysis, compared to those with private insurance, those with Medicaid, a public insurance program for low-income Americans, was associated with lower likelihood of prescribing of broadspectrum antibiotics (adjusted odds ratio (OR) 0.496, p = 0.003), so were those without health insurance (adjusted OR 0.499, p = 0.028), and those with Medicare, a public insurance program for the elderly or disabled adults (adjusted OR 0.666, p = 0.091). CONCLUSIONS: In the case of ARTI, those with private insurance were substantially more likely to be prescribed with broad-spectrum antibiotics, where the society may be better off if such overuse of antibiotics could be reduced. Individual feedback was provided to practitioners during regional meetings together with expert presentations and educative leaflets. RESULTS: Every second child with respiratory infection was treated with antibiotics. The most frequent drugs in DDD were macrolides (22.6%), followed by beta-lactamase sensitive penicillins (19.5%) and cephalosphorines (18.4%). Best pediatricians (20% of the group) were significantly different compared to the rest in majority of the quality bar indexes: less patients treated with ATB (31% vs. 51%); lower proportion of ATB in treatment (in EUR: 51% vs. 73%, in DDD: 28% vs. 51%); lower ATB costs per patient (−15%); lower aminopenicillins usage in acute tonsillopharyngitis (6% vs. 16%); lower ATB ratio in acute sinusitis (43% vs. 57%); however high ratio of macrolides was the problem across all groups. Higher prescription quality and lower ATB costs correlated together. There was significant decrease of ATB costs induced by one pediatrician during six years of the project (−50%). CONCLUSIONS: S-MedDial project represents an option for increase of antibiotics prescription quality using the prescribing practitioners' education. Analysis of prescription habits is suitable not only for cost control but also for antibiotics prescription implications on resistance trends. Longterm integrated educational program leads to prescription habits change and better quality of care.
PRS45 INTEGRATED EDUCATIONAL PROJECT WITH INDIVIDUAL FEEDBACK FROM CLAIMS DATA LEADS TO IMPROVED ANTIBIOTIC PRESCRIPTION AND RESISTANCE DECREASE

PRS46 TEN YEAR TRENDS IN PRESCRIPTION OF CHRONIC OBSTRUCTIVE PULMONARY MEDICATION AMONG ADULTS FROM 1996 TO 2005
Mehta H, Patel J, Parikh R, Aparasu RR, Sherer J University of Houston, Houston, TX, USA OBJECTIVES: Many guidelines were released during the past decade which tried to explain appropriate drug use for patients diagnosed with COPD. Medication use in COPD is also associated with issues related to adherence and side effects. The purpose of this study was to determine trends in prescription of COPD drugs in ambulatory setting and assess the rate of change in different drug classes. METHODS: We combined National Ambulatory Care Settings (NAMCS) and National Hospital Ambulatory Care Settings (NHAMCS) data from year 1996 to 2005. For trend analysis, data were stratified in 2-year periods. All adult visits with only primary diagnosis of COPD 492, 496) were included in analysis and drug categories were identified using National Drug Codes. Descriptive analysis was carried out to determine patterns in drug prescription across years and four separate multivariate logistic models, dependent variable being drug class and independent variable being year, were constructed to identify rate of change in drug use across years while controlling for age, race, sex and smoking status. RESULTS: From 1996-97 to 2004-05, total COPD visits have been increased from 0.59% to 0.77%; Prescription of anticholinergics and inhaled corticosteroids increased (17.47% to 33.48% and 12.63% to 35.19% respectively), whereas beta-agonist had no upward trend (29.46% to 29.53%). In year 1996-97, beta-agonist was the highly prescribed drug (29.46%) whereas in 2004-05, anticholinergics (33.48%) and inhaled corticosteroids (35.19%) were the top prescribed medications. From year 1996 to 2005, prescription of anticholinergics (OR-1.088; CI-1.029-1.151) and inhaled corticosteroids (OR-1.132; CI-1.065-1.203) increased, beta agonist use has decreased (OR-0.916; CI-0.866-0.969) whereas there was no change for systemic corticosteroids (OR-1.034; CI-0.979-1.092). CONCLU-SIONS: Overall drug utilization for COPD is increasing steadily. Use of bronchodilators is increasing which is in accordance with Global initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Corticosteroid use which is increasing should be based on risk to benefit ratio. To compare three common risk adjustment models when estimating health care costs. METHODS: Using data from U.S. claims databases, the effect of treatment on total health care expenditures among asthma patients was estimated. Reimbursement amounts were dollars paid by the health plan to the provider including patient co-payments and deductibles. Doctors' prescribing patterns were used as an instrumental variable for treatment choice. Propensity score matching was employed using the nearest neighbor matching algorithm. Generalized linear model was used as an alternative risk adjustment technique. RESULTS: Patients treated with control medication were younger, more likely to live in the northeast and south of the United States and have a higher Charlson comorbidity score, Elixhauser score and chronic disease score relative to patients treated with reliever medication. The difference between one year health care costs for reliever and controller medication was $2,345 by propensity score matching, $2,195 by generalized linear model, and $2,997 by instrumental variable approach. The difference was statistically significant. CONCLU-SIONS: After adjusting for patient clinical and demographic characteristics, controller medication was less costly than reliever medication. The choice of risk adjustment was important. The technique that controlled for both observed and unobserved biases (instrumental variable technique) provided a difference of almost 30% higher than the other techniques.
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